Replies to post #109333 on Biotech Values

[DewDiligence]

Teva issues 2012 non-GAAP EPS guidance of $5.48-5.68:

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1641774&highlight=

At the current share price, the midpoint of the 2012 guidance range represents a P/E of about 7.5x, which shows how far Teva’s star has fallen in the past year or two.

Without saying so formally, Teva has clearly backed off from its 2015 sales and earnings guidance issued in early 2010 (#msg-56956538).